Patents Assigned to Kite Pharma, Inc.
-
Publication number: 20240131068Abstract: The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL-18), compositions comprising the T cells, and methods of generating and/or using the T cells to treat diseases associated with the expression of CD19.Type: ApplicationFiled: October 17, 2023Publication date: April 25, 2024Applicants: Kite Pharma, Inc., The Trustees of the University of PennsylvaniaInventors: Neil C. Sheppard, Yanping Luo, David Barrett, Regina Young
-
Publication number: 20240132841Abstract: The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.Type: ApplicationFiled: October 5, 2023Publication date: April 25, 2024Applicant: Kite Pharma, Inc.Inventors: Felipe Bedoya, David Barrett, Vijay Gopal Reddy Peddareddigari, Namrata Choudhari, Matthew VanPelt
-
Publication number: 20240123068Abstract: The disclosure relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The disclosure also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.Type: ApplicationFiled: October 18, 2023Publication date: April 18, 2024Applicants: Kite Pharma, Inc., The Trustees of the University of PennsylvaniaInventors: Neil C. Sheppard, Yanping Luo, David Barrett, Regina Young
-
Publication number: 20240082307Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.Type: ApplicationFiled: August 24, 2023Publication date: March 14, 2024Applicants: Kite Pharma, Inc., Ofc of Tech Transfer, NIHInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Publication number: 20240018457Abstract: A method for bioprocessing includes the steps of providing a bioprocessing system having a first bioreactor vessel and a second bioreactor vessel, activating a population of cells in the first bioreactor vessel, genetically modifying the population of cells to produce a population of genetically modified cells, and expanding the population of genetically modified cells within the first bioreactor vessel and the second bioreactor vessel.Type: ApplicationFiled: December 14, 2021Publication date: January 18, 2024Applicants: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC, KITE PHARMA, INC.Inventors: PANTELEIMON ZOTOS, YARDEN SIVAN GRATCH, ISABELLE DALLE FUSINE, KASHAN ALI SHAIKH, ALICJA MARIA KROL, NATE W. FREUND, ERWIN V. CAMMAART, ANTHONY P. SWANDA
-
Publication number: 20240002777Abstract: A kit for magnetic cell isolation includes first stopcock manifold having at least four stopcocks, a separation chamber configured for use with a centrifugal processing chamber of the cell processing device, the separation chamber in fluid communication with the first stopcock manifold, a mixing bag configured for use with a heating/cooling mixing chamber of a cell processing device, the mixing bag in fluid communication with the first stopcock manifold, a second stopcock manifold having at least four stopcocks, the second stopcock manifold in fluid communication with the first stopcock manifold, a magnetic cell isolation holder in fluid communication with the second stopcock manifold, the magnetic cell isolation holder configured for use with a magnetic field generator of a magnetic cell isolation device, and a plurality of cell processing bags in fluid communication with the first and/or second stopcock manifolds.Type: ApplicationFiled: December 14, 2021Publication date: January 4, 2024Applicants: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC, KITE PHARMA, INC.Inventors: PIERRE-YVES CHASSOT, OLIVER LINK, FEDERICO ZANONI, MARK TIMMINS, KASHAN ALI SHAIKH, MARINE DE LAGENESTE, DENNIS CHEROK, YANN THOUEMENT, YORICK HEIMBERG, BERTRAND FOUCAUT, JULIEN CAMISANI, KENT YOUNG, SIMON GARDINER, ANTHONY P. SWANDA
-
Publication number: 20230416666Abstract: A bioreactor vessel includes a base having a plurality of through openings, a lid connected to the base via a plurality of heat stakes, and a gas-permeable, liquid impermeable membrane sandwiched between the base and the lid and held in position by the plurality heat stakes.Type: ApplicationFiled: December 14, 2021Publication date: December 28, 2023Applicants: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC, KITE PHARMA, INC.Inventors: NICOLAS PETITFOURG, ANDREU FONTOVA SOSA, MARK TIMMINS, DENNIS CHEROK, FERNANDO FRAGA, DONALD FRASER, NATE W. FREUND
-
Patent number: 11834654Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.Type: GrantFiled: November 10, 2020Date of Patent: December 5, 2023Assignee: Kite Pharma, Inc.Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
-
Patent number: 11820823Abstract: Isolated antigen binding molecules that specifically bind to a polypeptide comprising the alpha chain of the constant region of a T cell receptor (TCR) are provided. The antigen binding molecules may be used in the methods provided herein.Type: GrantFiled: October 26, 2018Date of Patent: November 21, 2023Assignee: Kite Pharma, Inc.Inventors: Stephanie Astrow, Stuart Sievers, Jed Wiltzius
-
Patent number: 11793834Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.Type: GrantFiled: December 11, 2019Date of Patent: October 24, 2023Assignee: Kite Pharma, Inc.Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
-
Patent number: 11779601Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.Type: GrantFiled: May 27, 2016Date of Patent: October 10, 2023Assignees: Kite Pharma, Inc., The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Patent number: 11723923Abstract: Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.Type: GrantFiled: August 6, 2019Date of Patent: August 15, 2023Assignees: Kite Pharma, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Arianne Perez, Marianna Sabatino, Steven A. Rosenberg, Nicholas P. Restifo
-
Patent number: 11708401Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.Type: GrantFiled: June 21, 2019Date of Patent: July 25, 2023Assignee: Kite Pharma, Inc.Inventors: Peter Emtage, Gabrielle Romain, Rosa Vincent, Sarah Wyman
-
Publication number: 20230158075Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: ApplicationFiled: September 27, 2022Publication date: May 25, 2023Applicants: Kite Pharma Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Patent number: 11608517Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499) and KPGSG (SEQ ID NO: 500) are provided. The antigen binding molecules can be used in the methods provided herein.Type: GrantFiled: October 29, 2019Date of Patent: March 21, 2023Assignee: Kite Pharma, Inc.Inventors: Jed Wiltzius, Stuart Sievers, Arianne Perez Garcia
-
Patent number: 11572388Abstract: The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.Type: GrantFiled: May 19, 2020Date of Patent: February 7, 2023Assignee: Kite Pharma, Inc.Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
-
Patent number: 11505613Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: GrantFiled: September 12, 2019Date of Patent: November 22, 2022Assignee: Kite Pharma, Inc.Inventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Jonathan Belk
-
Patent number: 11491187Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: GrantFiled: April 10, 2018Date of Patent: November 8, 2022Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Patent number: 11390655Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a modified hinge, transmembrane and/or intracellular domain disclosed herein. Some aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) comprising the costimulatory domain disclosed herein. Other aspects of the disclosure relate to cells comprising the CAR and use in a T cell therapy.Type: GrantFiled: November 15, 2018Date of Patent: July 19, 2022Assignee: Kite Pharma, Inc.Inventors: Stuart A. Sievers, Jed J. W. Wiltzius
-
Patent number: 11384155Abstract: Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.Type: GrantFiled: March 10, 2020Date of Patent: July 12, 2022Assignee: Kite Pharma, Inc.Inventors: Jed Wiltzius, Stuart Sievers